Nucleo
AI-powered cancer diagnostics and medical imaging platform for oncology
nucleoresearch.com ↗📍 San Francisco, CA
Verified Data
“Based on $4M seed funding and 2-10 employee team size, typical early-stage B2B SaaS metrics suggest low hundreds of thousands in ARR for a company in validation stage”
Company Profile
Contact
@Nucleo_ResearchStrategic Analysis
Strategy
Building agentic AI platform specifically for oncology workflows, targeting radiologists and oncologists with enterprise SaaS model. Focusing on clinical validation through research partnerships and regulatory pathways for medical AI. Leveraging Y Combinator network and $4M seed funding to establish product-market fit in cancer diagnostics.
Tactics
Partnering with clinical research institutions like NLST for validation studies. Custom enterprise pricing model targeting hospitals and large healthcare systems. Building technical credibility through published accuracy metrics (98% sarcopenia detection). Founder-led sales through medical conferences and direct outreach to oncology departments.
Competitive Positioning
Differentiates from general medical AI tools by focusing specifically on oncology workflows and agentic AI capabilities. Competes with broader radiology AI platforms but positions as the specialized solution for cancer care. Emphasizes clinical validation and regulatory compliance as key differentiators from generic computer vision tools.
Marketing Approach
Thought leadership through medical conferences and clinical research publications. Direct sales to healthcare institutions leveraging founder expertise in oncology. Building credibility through Forbes recognition and clinical validation studies. Targeting radiologists and oncologists through professional networks and medical journals.
Notable
Y Combinator F25 batch, Forbes 30 Under 30 Europe 2026 recognition for co-founder
🔗 Source ↗Tech Stack
AWS
Cloudflare
SlackGoogle WorkspaceRecent News
Related AI Healthcare Companies
Discovery Sources
Signals
Evidence
We're the first [AI system aimed at oncology].
$4M seed
2-10 employees
98% accuracy in sarcopenia detection; reduces diagnostic timeline from weeks to days